Dunn J, Nylander W, Richie R
Department of Surgery, Vanderbilt University Medical Center, Nashville, TN 37232.
Surgery. 1987 Nov;102(5):784-9.
The central venous dialysis catheter has gained wide acceptance for short-term hemodialysis with the realization of the need to spare peripheral extremity vessels for the creation of more durable internal arteriovenous fistulas. The Hemocath (Quinton Instrument Co., Seattle, Wash.), a soft, silicone rubber, double-lumen central venous dialysis catheter, was introduced as a permanent access device in 1984. A prospective evaluation of 53 catheters placed in 51 patients over a 9-month period is presented. Forty-nine catheters were placed for temporary access and four were placed for permanent access. All 53 catheters were discontinued after functioning an average of 63.9 days (range, 5 to 324 days). No major complications occurred during insertion or on dialysis. One catheter fragmented during removal and was retrieved in the operating room. Infection led to the removal of 17 catheters (34.7%). Thrombosis occurred in 11 catheters and was the cause of removal in two (4.1%). Excluding the two catheters that functioned at the time of the patient's deaths and those placed for permanent access, 91.5% of the catheters performed successfully as temporary accesses devices until permanent access sites were available for use. The catheter provided reliable, relatively safe, and easily maintained central venous access for hemodialysis.
随着人们认识到需保留外周血管以建立更持久的动静脉内瘘,中心静脉透析导管在短期血液透析中已得到广泛应用。1984年,Hemocath(华盛顿州西雅图市Quinton仪器公司)作为一种永久性血管通路装置被引入,它是一种柔软的硅橡胶双腔中心静脉透析导管。本文介绍了对51例患者在9个月内放置的53根导管进行的前瞻性评估。其中49根导管用于临时血管通路,4根用于永久性血管通路。所有53根导管在平均使用63.9天(范围为5至324天)后停用。插入过程中或透析时未发生重大并发症。1根导管在拔除时断裂,后在手术室取出。感染导致17根导管(34.7%)被拔除。11根导管发生血栓形成,其中2根(4.1%)因血栓形成而被拔除。排除在患者死亡时仍在使用的2根导管以及用于永久性血管通路的导管,91.5%的导管作为临时血管通路装置成功发挥作用,直至永久性血管通路可供使用。该导管为血液透析提供了可靠、相对安全且易于维护的中心静脉通路。